Surgery Partners Jumps 23% in Premarket Trading as Bon Secours Nears $6 Billion Takeover, FT Reports

Surgery Partners shares jumped 23% in premarket trading on Monday after the Financial Times reported that Bon Secours Mercy Health, a U.S. not-for-profit health system, is in late-stage talks to buy a majority stake in the short-stay surgery operator, in a take-private that would value the company at roughly $6 billion including debt.

The move repriced the stock most of the way to the reported deal value before the regular session began. Public's market data showed the shares trading at $19.38 in premarket trading at 6:00 a.m. ET, up 23.05% from Friday's close of $15.75, after an $18.80 premarket open; an earlier Investing.com report put the gain at 21.2%, and Seeking Alpha listed the stock among Monday's biggest gainers. Premarket trading is thin, and a gain measured before 9:30 a.m. can narrow or reverse once the full market opens — but the direction is unambiguous: investors are treating the reported talks as credible enough to bid the shares to within about 3% of the reported $20-a-share value (a comparison calculated from the reported value and the 6:00 a.m. premarket price).

What has been reported — and what has not

The Financial Times reported on Sunday, citing people familiar with the matter, that Bon Secours Mercy Health is in late-stage talks to buy a majority stake in Surgery Partners at about $20 a share, in a deal that would value the company at roughly $6 billion including debt and could be announced as early as Monday. Bain Capital, the largest shareholder with almost 40% of the company, would retain its stake under the reported structure. That is the whole of the verified record so far: neither Bon Secours Mercy Health nor Surgery Partners responded to a request for comment outside regular business hours on Sunday, and as of Monday morning no definitive agreement, company statement or filing had been published. Talks at this stage can still fail, be repriced, or slip past the reported announcement window, and the article that follows treats every deal term as reported, not agreed.

Why a hospital system would buy a surgery-center operator

The strategic logic is the migration of surgery out of hospitals. Surgery Partners, headquartered in Brentwood, Tennessee, runs one of the largest U.S. networks of ambulatory surgery centers and short-stay surgical hospitals — more than 200 locations in 30 states by the company's own description, and 178 surgical facilities at the end of June — built around procedures that do not need a full hospital admission. For a not-for-profit hospital system, a majority stake buys that outpatient platform at scale in one transaction instead of years of building or buying centers market by market. The reported network the Financial Times described — 176 surgery centers and hospitals across 30 states — differs from the company's location count because the definitions differ, but either way it is the outpatient footprint, not the hospital business, that is the prize.

The debt is most of the headline number

The $6 billion figure is an enterprise value, and most of it is debt the buyer would step into rather than cash paid to shareholders. The reported structure includes about $3.5 billion of debt; the company's total debt stood at $3.75 billion on June 30, 2026, and balance-sheet leverage under its credit agreement was 4.4 times adjusted earnings at the end of the second quarter. Surgery Partners has spent the autumn shrinking that load: on September 17 it completed the sale of its Idaho Falls hospital interests to Intermountain Health, and received $797 million in gross proceeds and $587 million in net cash proceeds at closing, with the proceeds used primarily to pay down debt. The same release cut full-year 2026 guidance to revenue of $3.08 billion to $3.18 billion and adjusted EBITDA of at least $489 million, reflecting the Idaho facilities' removal for the rest of the year. A buyer negotiating this month is pricing the smaller, less leveraged company that sale left behind.

A buyer returns to a company that has resisted deals before

This is not Surgery Partners' first approach. The company rejected a Bain Capital take-private offer in June last year, saying it was unable to agree to the terms set by the private equity group, and the Financial Times account describes more than a year of stop-start sale efforts, including the episode in which Surgery Partners walked away from a Bain-led go-private deal last year at a $6.7 billion enterprise value — a higher headline value than the one now reported, struck before the Idaho sale changed the company's shape. The operating record explains both the interest and the discount to that earlier mark: second-quarter revenue rose 2.7% to $848.9 million, but adjusted EBITDA eased to $125.2 million from $129.0 million a year earlier and the company posted a $15.0 million net loss for the quarter. A strategic buyer that can put its own patient volume through those centers can underwrite value a financial buyer, or the public market at $15.75, was not paying for.

What would confirm it

Confirmation has a specific shape: a definitive agreement, a statement from either company, or a securities filing — any of which could still arrive on Monday, the announcement window the report named. Until one appears, the verified facts are a Sunday report of late-stage talks at about $20 a share, silence from both companies, and a premarket price that has already voted. The regular session will show whether the move holds at full volume, and the open questions a filing would have to answer are the final price and stake, how the purchase is financed, what happens to the remaining debt, and which state and antitrust approvals a hospital-system acquisition of a 30-state surgery network requires. If the window passes with no announcement, the premarket gain is the part of this story most exposed to reversal.